Arshad, M., Azad, A., Chan, P., Vigneswara, V., Feldinger, K., Nafi, S., . . . Kong, A. (2024). Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models. Springer Nature [academic journals on nature.com].
芝加哥风格引文Arshad, M., et al. Neratinib Could Be Effective as Monotherapy or in Combination with Trastuzumab in HER2-low Breast Cancer Cells and Organoid Models. Springer Nature [academic journals on nature.com], 2024.
MLA引文Arshad, M., et al. Neratinib Could Be Effective as Monotherapy or in Combination with Trastuzumab in HER2-low Breast Cancer Cells and Organoid Models. Springer Nature [academic journals on nature.com], 2024.
警告：这些引文格式不一定是100％准确.